TGFB1 and benign prostatic hyperplasia: This was evidenced by downregulation of DHT, reduced PW and PI, elevated proapoptotic Caspase-3, SOD, CAT, and TAC levels and lowered proinflammatory TGF-β1, cellular DNA damage, and MDA, and regression of epithelial and stromal hyperplasia in experimental BPH rats through its antioxidative, antiproliferative, and proapoptotic properties.